Antibody-dependent cell-mediated cytotoxicity can protect PBMC from infection by cell-associated HIV-1.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Antibody-dependent cell-mediated cytotoxicity can protect PBMC from infection by cell-associated HIV-1.

1999 Feb;90(2):203-12. Unique Identifier : AIDSLINE MED/99180792
Hildreth JEK; Hampton R; Halsey NA; Department of Pharmacology and Molecular Sciences, The Johns; Hopkins University School of Medicine, Baltimore, Maryland 21205,; USA.

Abstract: We have developed a novel in vitro assay system to study the role of antibody-dependent cell-mediated cytotoxicity (ADCC) in protection against HIV-1 infection by cell-associated virus. HIV-1-infected NK-resistant cells are mixed with specific antibody and unstimulated PBMC and ADCC is allowed to occur over several hours. The PBMC are then activated and cultured to allow virus replication in newly infected T cells. To ensure that ADCC is the only mechanism by which protection could occur we have used haptenated (TNP) infected cells and anti-hapten antibody. Anti-hapten sera completely protected PBMC from infection by haptenated HIV-1-infected cells in ADCC protection assays. F(ab')2 fragments of anti-hapten IgG showed no protection, confirming that ADCC was responsible for protection by anti-hapten IgG. PCR analysis for HIV-1 DNA confirmed the elimination of infected cells. We believe this to be the first direct demonstration that ADCC alone can protect PBMC from infection by cell-associated HIV-1. Copyright 1999 Academic Press.

Keywords: JOURNAL ARTICLE *Antibody-Dependent Cell Cytotoxicity DNA, Viral/ANALYSIS Haptens/IMMUNOLOGY Human HIV Antibodies/METABOLISM HIV Infections/*IMMUNOLOGY/PREVENTION & CONTROL/VIROLOGY HIV-1/*IMMUNOLOGY/PATHOGENICITY IgG/METABOLISM In Vitro Killer Cells, Natural/IMMUNOLOGY Leukocytes, Mononuclear/*IMMUNOLOGY/*VIROLOGY Neutralization Tests Support, U.S. Gov't, P.H.S. T-Lymphocytes/IMMUNOLOGY/VIROLOGY Trinitrobenzenes/IMMUNOLOGY
990630
A9960949

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .